BIOMX INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4048 USD | +1.20% |
|
+12.41% | +44.57% |
| 05-21 | Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024 | |
| 05-20 | BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the BiomX First Quarter ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.4
USD
Average target price
2.833
USD
Spread / Average Target
+608.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.57% | 27.92M | |
| +14.73% | 118B | |
| +12.99% | 106B | |
| -3.09% | 24.28B | |
| +1.14% | 21.96B | |
| -9.35% | 18.16B | |
| -42.28% | 16.37B | |
| -17.34% | 15.56B | |
| +4.43% | 13.63B | |
| +27.81% | 12.27B |
- Stock Market
- Equities
- PHGE Stock
- News BiomX Inc.
- Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024
